SCHEMBL3986669

SCHEMBL3986669

Cc1ccccc1Cn1nc(C)c2c(c(O)c3n2CCN(C)C3=O)c1=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.36
ADORA2A P29274 1/20 0.36
MAPT P10636 1/20 0.35
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
PKM P14618 1/20 0.35
PKLR P30613 1/20 0.35
CHRM1 P11229 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
P2RX7 Q99572 1/20 0.34
NPBWR1 P48145 1/20 0.34
TRPC5 Q9UL62 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386722 0.89 MEN1 (0.44) KDM4ELMNAADORA2AMAPTPKM
SCHEMBL16253746 0.88 P2RX7 (0.36) TSHRKDM4ELMNAADORA2AMAPT
SCHEMBL3985461 0.88 PDE5A (0.39) MAPTMEN1KMT2A
SCHEMBL3986391 0.88 NPBWR1 (0.37) KMT2ANPBWR1
SCHEMBL3991515 0.86 PKM (0.38) TSHRPKMPKLRMEN1KMT2A
SCHEMBL3988165 0.86 SLC22A12 (0.41) KDM4EMEN1KMT2AP2RX7ALDH1A1
SCHEMBL1386093 0.84 LMNA (0.34) LMNAMAPTPKMPKLRSMN1; SMN2
SCHEMBL3985863 0.83 PKM (0.35) TSHRLMNAMAPTPKMPKLR
SCHEMBL3985480 0.83 PKM (0.36) PKMPKLRP2RX7
SCHEMBL3985002 0.83 NPBWR1 (0.35) LMNAPKMPKLRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US claimed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US claimed
EP-1756114-B1 HIV INTEGRASE INHIBITORS MERCK SHARP & DOHME (US) 2014-11-19 EP disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-7538112-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2009-05-26 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed
US-20080287394-A1 Hiv Integrase Inhibitors MERCK & CO., INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287394-A1 Hiv Integrase Inhibitors DHPS, DPYD, TYMP TSHR 3581/4885KDM4E 377/4885LMNA 3682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.